For example, combination of multiple plasma biomarkers (Aβ42/40, neurofilament light, glial fibrillary acidic protein (GFAP) and p-tau181) has shown to improve accuracy of identifying Aβ+ cases in DLB [86▪]. This evidence concerns the gene NEFL and Lewy body dementia.